Pictet Asset Management Holding SA grew its stake in shares of Kodiak Sciences Inc. (NASDAQ:KOD – Free Report) by 20.0% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 79,218 shares of the company’s stock after buying an additional 13,203 shares during the period. Pictet Asset Management Holding SA owned 0.13% of Kodiak Sciences worth $7,238,000 at the end of the most recent reporting period.
Several other hedge funds also recently bought and sold shares of KOD. KBC Group NV purchased a new stake in shares of Kodiak Sciences in the first quarter valued at $39,000. Sterling Capital Management LLC boosted its stake in shares of Kodiak Sciences by 850.0% during the third quarter. Sterling Capital Management LLC now owns 1,311 shares of the company’s stock valued at $124,000 after acquiring an additional 1,173 shares during the last quarter. EverSource Wealth Advisors LLC increased its position in Kodiak Sciences by 94.5% during the 1st quarter. EverSource Wealth Advisors LLC now owns 1,927 shares of the company’s stock worth $73,000 after purchasing an additional 936 shares in the last quarter. Simplicity Wealth LLC purchased a new stake in Kodiak Sciences during the 3rd quarter worth about $263,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new stake in Kodiak Sciences during the 3rd quarter worth about $304,000. Hedge funds and other institutional investors own 89.06% of the company’s stock.
Kodiak Sciences Price Performance
Shares of Kodiak Sciences stock opened at $111.19 on Monday. Kodiak Sciences Inc. has a fifty-two week low of $18.15 and a fifty-two week high of $112.79. The firm has a market cap of $6.99 billion, a PE ratio of -27.25 and a beta of 2.02. The business’s fifty day moving average is $76.72 and its two-hundred day moving average is $45.75.
Kodiak Sciences (NASDAQ:KOD – Get Free Report) last posted its quarterly earnings data on Thursday, November 12th. The company reported ($1.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.06) by $0.01. Equities research analysts anticipate that Kodiak Sciences Inc. will post -3.97 EPS for the current year.
Wall Street Analysts Forecast Growth
A number of research analysts have issued reports on the stock. JPMorgan Chase & Co. upped their target price on shares of Kodiak Sciences from $56.00 to $66.00 and gave the company an “overweight” rating in a report on Monday, August 3rd. Lifesci Capital raised their price target on shares of Kodiak Sciences from $85.00 to $145.00 and gave the stock an “outperform” rating in a research note on Monday, September 28th. Wall Street Zen upgraded shares of Kodiak Sciences from a “sell” rating to a “hold” rating in a report on Saturday. Weiss Ratings downgraded shares of Kodiak Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, October 6th. Finally, The Goldman Sachs Group assumed coverage on shares of Kodiak Sciences in a research report on Wednesday, September 30th. They issued a “neutral” rating and a $103.00 price objective for the company. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Kodiak Sciences currently has a consensus rating of “Moderate Buy” and an average price target of $109.00.
Get Our Latest Analysis on KOD
Insiders Place Their Bets
In other Kodiak Sciences news, Director Bros. Advisors Lp Baker bought 807,840 shares of Kodiak Sciences stock in a transaction that occurred on Monday, September 28th. The shares were purchased at an average cost of $72.57 per share, for a total transaction of $58,624,948.80. Following the completion of the transaction, the director owned 19,121,134 shares of the company’s stock, valued at $1,387,620,694.38. This represents a 4.41% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders bought 2,188,845 shares of company stock worth $181,326,862 in the last quarter. Corporate insiders own 44.40% of the company’s stock.
About Kodiak Sciences
Kodiak Sciences is a clinical-stage biopharmaceutical company focused on developing treatments for retinal and other eye diseases. The company’s research centers on therapies designed to address conditions involving damage to the retina and vision loss. Kodiak’s technology platform combines therapeutic antibodies with a biopolymer to create antibody biopolymer conjugates, which are designed to provide sustained treatment effects. Its development programs have included KSI-301, an investigational therapy targeting vascular endothelial growth factor (VEGF) for retinal diseases.
Read More
- Five stocks we like better than Kodiak Sciences
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Kodiak Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kodiak Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
